| Trial | Title | Study Record Detail | Phase | Sponsor/Collaborator |
|---|---|---|---|---|
| A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | NCT01101594 | Phase I / Phase II | Immunomedics, Inc. |
Last Editorial Review: July 15, 2016
Home Milatuzumab-Doxorubicin (IMMU-110 / hLL1-Dox) Clinical Trials
